Rafferty Asset Management LLC Has $4.44 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Rafferty Asset Management LLC lessened its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 11.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 122,943 shares of the company's stock after selling 15,154 shares during the quarter. Rafferty Asset Management LLC owned 0.17% of SpringWorks Therapeutics worth $4,442,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Huntington National Bank raised its stake in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after buying an additional 192 shares during the period. AlphaQuest LLC raised its stake in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of SpringWorks Therapeutics in the 4th quarter valued at about $45,000. KBC Group NV raised its stake in shares of SpringWorks Therapeutics by 59.1% in the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after purchasing an additional 978 shares during the period. Finally, US Bancorp DE raised its stake in shares of SpringWorks Therapeutics by 56.0% in the 4th quarter. US Bancorp DE now owns 4,336 shares of the company's stock valued at $157,000 after purchasing an additional 1,556 shares during the period.

Insider Buying and Selling

In related news, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the completion of the transaction, the chief operating officer now owns 169,712 shares in the company, valued at approximately $9,203,481.76. This trade represents a 10.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Bhavesh Ashar sold 1,016 shares of SpringWorks Therapeutics stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now owns 62,053 shares of the company's stock, valued at $3,797,023.07. The trade was a 1.61% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 146,944 shares of company stock worth $8,439,479. Company insiders own 7.83% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on SWTX. Guggenheim reissued a "neutral" rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Wedbush reissued a "neutral" rating and issued a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Barclays reissued an "equal weight" rating and issued a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. HC Wainwright reaffirmed a "neutral" rating and issued a $47.00 target price (down previously from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, April 30th. Finally, TD Cowen reaffirmed a "hold" rating and issued a $47.00 target price (down previously from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, SpringWorks Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $52.57.

SpringWorks Therapeutics Stock Performance

NASDAQ:SWTX opened at $46.11 on Monday. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00. The company has a market cap of $3.47 billion, a P/E ratio of -13.25 and a beta of 0.77. The stock's 50-day simple moving average is $43.95 and its 200 day simple moving average is $42.32.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The business had revenue of $49.09 million for the quarter, compared to the consensus estimate of $64.19 million. As a group, equities analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.